Cargando…

Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters

BACKGROUND: Olanzapine (OLZ) is one of the most prescribed atypical antipsychotic drugs but its use is associated with unfavorable metabolic abnormalities. N-desmethyl-olanzapine (DMO), one of the OLZ metabolites by CYP1A2, has been reported to have a normalizing action on metabolic abnormalities, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Mong-Liang, Lin, Chia-Hui, Chen, Yi-Chuan, Yang, Huai-Chih, Wu, Tzu-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669135/
https://www.ncbi.nlm.nih.gov/pubmed/23741510
http://dx.doi.org/10.1371/journal.pone.0065719
_version_ 1782271705431932928
author Lu, Mong-Liang
Lin, Chia-Hui
Chen, Yi-Chuan
Yang, Huai-Chih
Wu, Tzu-Hua
author_facet Lu, Mong-Liang
Lin, Chia-Hui
Chen, Yi-Chuan
Yang, Huai-Chih
Wu, Tzu-Hua
author_sort Lu, Mong-Liang
collection PubMed
description BACKGROUND: Olanzapine (OLZ) is one of the most prescribed atypical antipsychotic drugs but its use is associated with unfavorable metabolic abnormalities. N-desmethyl-olanzapine (DMO), one of the OLZ metabolites by CYP1A2, has been reported to have a normalizing action on metabolic abnormalities, but this remains unclear. Our aim was to explore the correlation between the concentrations of OLZ or DMO with various metabolic parameters in schizophrenic patients. METHODS: The chromatographic analysis was carried out with a solvent delivery system coupled to a Coulochem III coulometric detector to determine OLZ and DMO simultaneously in OLZ-treated patients. The correlation between the concentration of OLZ or DMO and the metabolic parameters was analyzed by the Spearman rank order correlation method (r (s)). PRINCIPAL FINDINGS: The established analytical method met proper standards for accuracy and reliability and the lower limitation of quantification for each injection of DMO or OLZ was 0.02 ng. The method was successfully used for the analysis of samples from nonsmoking patients (n = 48) treated with OLZ in the dosage range of 5–20 mg per day. There was no correlation between OLZ concentrations and tested metabolic parameters. DMO concentrations were negatively correlated with glucose (r (s) = –0.45) and DMO concentrations normalized by doses were also negatively correlated with insulin levels (r (s) = –0.39); however, there was a marginally positive correlation between DMO and homocysteine levels (r (s) = +0.38). CONCLUSIONS: The observed negative correlations between levels of DMO and glucose or insulin suggest a metabolic normalization role for DMO regardless of its positive correlation with a known cardiovascular risk factor, homocysteine. Additional studies of the mechanisms underlying DMO’s metabolic effects are warranted.
format Online
Article
Text
id pubmed-3669135
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36691352013-06-05 Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters Lu, Mong-Liang Lin, Chia-Hui Chen, Yi-Chuan Yang, Huai-Chih Wu, Tzu-Hua PLoS One Research Article BACKGROUND: Olanzapine (OLZ) is one of the most prescribed atypical antipsychotic drugs but its use is associated with unfavorable metabolic abnormalities. N-desmethyl-olanzapine (DMO), one of the OLZ metabolites by CYP1A2, has been reported to have a normalizing action on metabolic abnormalities, but this remains unclear. Our aim was to explore the correlation between the concentrations of OLZ or DMO with various metabolic parameters in schizophrenic patients. METHODS: The chromatographic analysis was carried out with a solvent delivery system coupled to a Coulochem III coulometric detector to determine OLZ and DMO simultaneously in OLZ-treated patients. The correlation between the concentration of OLZ or DMO and the metabolic parameters was analyzed by the Spearman rank order correlation method (r (s)). PRINCIPAL FINDINGS: The established analytical method met proper standards for accuracy and reliability and the lower limitation of quantification for each injection of DMO or OLZ was 0.02 ng. The method was successfully used for the analysis of samples from nonsmoking patients (n = 48) treated with OLZ in the dosage range of 5–20 mg per day. There was no correlation between OLZ concentrations and tested metabolic parameters. DMO concentrations were negatively correlated with glucose (r (s) = –0.45) and DMO concentrations normalized by doses were also negatively correlated with insulin levels (r (s) = –0.39); however, there was a marginally positive correlation between DMO and homocysteine levels (r (s) = +0.38). CONCLUSIONS: The observed negative correlations between levels of DMO and glucose or insulin suggest a metabolic normalization role for DMO regardless of its positive correlation with a known cardiovascular risk factor, homocysteine. Additional studies of the mechanisms underlying DMO’s metabolic effects are warranted. Public Library of Science 2013-05-31 /pmc/articles/PMC3669135/ /pubmed/23741510 http://dx.doi.org/10.1371/journal.pone.0065719 Text en © 2013 Lu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lu, Mong-Liang
Lin, Chia-Hui
Chen, Yi-Chuan
Yang, Huai-Chih
Wu, Tzu-Hua
Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
title Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
title_full Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
title_fullStr Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
title_full_unstemmed Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
title_short Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
title_sort determination of olanzapine and n-desmethyl-olanzapine in plasma using a reversed-phase hplc coupled with coulochemical detection: correlation of olanzapine or n-desmethyl-olanzapine concentration with metabolic parameters
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669135/
https://www.ncbi.nlm.nih.gov/pubmed/23741510
http://dx.doi.org/10.1371/journal.pone.0065719
work_keys_str_mv AT lumongliang determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters
AT linchiahui determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters
AT chenyichuan determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters
AT yanghuaichih determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters
AT wutzuhua determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters